A retrospective analysis of small molecule targeting inhibitor usage for lung cancer among outpatients in six major regions of China (2016-2022).

Gefitinib demonstrated only a borderline significant change in total cost ( P 1 = 0.127), though its proportional usage rose significantly ( P 2 < 0.001).

also in 11,409 other papers

Icotinib, Osimertinib, and Erlotinib exhibited strong statistical significance across both metrics ( P 1 and P 2 < 0.001), while Anlotinib’s total cost trend did not reach statistical significance ( P 1 = 0.108) despite a notable increase in proportional usage ( P 2 < 0.001).

also in 111,027 other papers

In four cities—Beijing, Shanghai, Guangzhou, and Zhengzhou—both trend tests yielded highly significant results ( P 1 < 0.001, P 2 < 0.001).

also in 132,142 other papers